SARS CoV-2 Clinical Trials

12 recruitingLast updated: June 18, 2026

There are 12 actively recruiting sars cov-2 clinical trials across 6 countries. Studies span Phase 1, Not Applicable, Phase 4, Early Phase 1, Phase 2. Top locations include Atlanta, Georgia, United States, Baton Rouge, Louisiana, United States, Birmingham, Alabama, United States. Updated daily from ClinicalTrials.gov.


SARS CoV-2 Trials at a Glance

12 actively recruiting trials for sars cov-2 are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Atlanta, Baton Rouge, and Birmingham. Lead sponsors running sars cov-2 studies include Columbia University, Fondazione IRCCS Policlinico San Matteo di Pavia, and Assistance Publique - Hôpitaux de Paris.

Browse sars cov-2 trials by phase

Treatments under study

About SARS CoV-2 Clinical Trials

Looking for clinical trials for SARS CoV-2? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new SARS CoV-2 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about SARS CoV-2 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Systemic Inflammatory Response SyndromeSARS CoV-2Respiratory distress syndrome+2 more
PEACHES BIOTECH50 enrolled3 locationsNCT06684379
Recruiting
Early Phase 1

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

SARS CoV-2 Post-Acute Sequelae
University of Alabama at Birmingham60 enrolled1 locationNCT05656105
Recruiting
Phase 1

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Long COVIDSARS CoV-2Neurodegeneration+1 more
Stephanie B. Seminara, MD40 enrolled1 locationNCT07224490
Recruiting
Phase 4

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

SARS CoV-2
ModernaTX, Inc.1,144 enrolled6 locationsNCT06585241
Recruiting
Phase 1

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

COVID-19SARS CoV-2
Rokote Laboratories Finland Oy20 enrolled1 locationNCT07416539
Recruiting

COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study

SARS CoV-2Intensive Care Unit
Hospices Civils de Lyon200 enrolled8 locationsNCT04392401
Recruiting

Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence

COVID-19SARS CoV-2Corona Virus Infection
Columbia University800 enrolled1 locationNCT04448145
Recruiting
Not Applicable

Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads

Cardiovascular DiseasesChronic Kidney DiseasesDiabetes Mellitus, Type 2+3 more
University of South Carolina500 enrolled1 locationNCT05370014
Recruiting

Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)

SARS CoV-2Liver Tumours
Fondazione IRCCS Policlinico San Matteo di Pavia40 enrolled1 locationNCT06914635
Recruiting

Viral Infection of HSPC Impacts Hematopoiesis

SARS CoV-2HIV-1
Assistance Publique - Hôpitaux de Paris45 enrolled1 locationNCT06458504
Recruiting
Phase 4

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

SARS CoV-2 Post-Acute Sequelae
Mount Sinai Hospital, Canada118 enrolled4 locationsNCT06792214
Recruiting
Not Applicable

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

Kawasaki DiseaseSARS CoV-2Retrovirus Infection
IRCCS Azienda Ospedaliero-Universitaria di Bologna120 enrolled5 locationsNCT06775457